| Trial ID: | L2569 |
| Source ID: | NCT02040012
|
| Associated Drug: |
Azp-531
|
| Title: |
A Study to Evaluate AZP531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: AZP-531|DRUG: Placebo
|
| Outcome Measures: |
Primary: To investigate the number of adverse events of single and multiple ascending doses AZP-531 in healthy volunteers, in overweight/obese volunteers, in patients with type 2 diabetes mellitus., 1 to 14 days | Secondary: To determine the plasma pharmacokinetic (PK) profile of AZP-531 after single and multiple doses, 1 to 14 days | Other: To obtain exploratory data on the effects of AZP-531 on the pharmacodynamic (PD) markers, 1 to 14 days
|
| Sponsor/Collaborators: |
Sponsor: Alizé Pharma
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
108
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2013-07
|
| Completion Date: |
2015-10
|
| Results First Posted: |
|
| Last Update Posted: |
2015-06-18
|
| Locations: |
Quintiles Drug Research Unit at Guy's Hospital, London, SE1 1YR, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT02040012
|
